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DNA methylationResearch on the pathogenicity of human papillomaviruses (HPVs) during cervical carcinogenesis often relies
on the study of homogenized tissue or cultured cells. This approach does not detect molecular
heterogeneities within the infected tissue. It is desirable to understand molecular properties in speciﬁc
histological contexts. We asked whether laser capture microdissection (LCM) of archival cervical tumors in
combination with real-time polymerase chain reaction and bisulﬁte sequencing permits (i) sensitive DNA
diagnosis of small clusters of formalin-ﬁxed cells, (ii) quantiﬁcation of HPV DNA in neoplastic and normal
cells, and (iii) analysis of HPV DNA methylation, a marker of tumor progression. We analyzed 26 tumors
containing HPV-16 or 18. We prepared DNA from LCM dissected thin sections of 100 to 2000 cells, and
analyzed aliquots corresponding to between nine and 70 cells. We detected nine to 630 HPV-16 genome
copies and one to 111 HPV-18 genome copies per tumor cell, respectively. In 17 of the 26 samples, HPV DNA
existed in histologically normal cells distant from the margins of the tumors, but at much lower
concentrations than in the tumor, suggesting that HPVs can infect at low levels without pathogenic changes.
Methylation of HPV DNA, a biomarker of integration of the virus into cellular DNA, could be measured only in
few samples due to limited sensitivity, and indicated heterogeneous methylation patterns in small clusters of
cancerous and normal cells. LCM is powerful to study molecular parameters of cervical HPV infections like
copy number, latency and epigenetics.© 2009 Elsevier Inc. All rights reserved.Introduction
The molecular biology of human papillomaviruses (HPVs) has
been extensively studied in vitro, in cell culture, and in clinical
samples, and the data garnered from these studies have led to detailed
information about the productive life cycle of HPVs and HPV induced
pathogenesis. Certain HPV types such as HPV-16 and HPV-18 are
sexually transmitted, and a fraction of the infections inwomen,mostly
those of epithelial cells at the squamo-columnar junction of the cervix,
can progress from subclinical infections to non-invasive cancer
precursors (cervical intraepithelial neoplasia) to carcinoma in situ
and invasive carcinomas (zur Hausen, 2002; Munoz et al., 2003;r Biology and Biochemistry,
x: +1 949 824 8551.
ll rights reserved.Bernard, 2005). Unfortunately, many experimental strategies provide
data that reﬂect the average property of large numbers of HPV
genomes or HPV infected cells. This overlooks the possibility that the
viral biology is heterogeneous in cell populations of differentiating
squamous epithelia (Lee and Laimins, 2007). Similarly the progression
of neoplasia generates histological heterogeneities due to sequential
mutations and clonal expansions. As a consequence, we have little
information about the spatial and temporal changes of HPV infections
at the same anatomic site. This limits our ability to detect HPVs in
subclinical and “latent” infections, and to discern patterns of
regulatory switches, sequential mutations and epigenetic changes
during carcinogenic progression. These problems can only be over-
come with techniques that target selected small groups of cells or
even individual cells.
Laser capture microdissection (LCM) uses a laser beam targeted at
tissue sections under microscopic control to isolate clusters of cells
Table 1
Quantitative real-time PCR detection of HPV-16 and HPV-18 in LCM generated samples
from squamous carcinomas of the cervix and in samples from adjacent normal
epithelial and mesenchymal tissue.
Name of tumor HPV genome copy number (CT HPV/CT HMBS)
Tumor Normal epithelium Stroma
HPV-16
T16-1 74 (14.8/20.0) b1 (24.1/21.3) b1 (27.9/26.6)
T16-2 X (15.6/pos.) 0 (neg./pos.) 0 (neg./pos.)
T16-3 X (14.5/pos.) 0 (neg./pos.) 0 (neg./pos.)
T16-4 630 (18.9/27.2) 0 (neg./28.2) 0 (neg./26.9)
T16-5 208 (14.5/21.8) 2 (26.8/26.7) b1 (27.0/24.0)
T16-6 104 (14.5/20.2) b1 (29.3/22.6) 0 (neg./22.3)
T16-7 9(20.1/22.2) b1 (25.1/21.5) 0 (neg./24.0)
T16-8 49 (17.8/22.4) b1 (32.0/22.3) 0 (neg./25.3)
T16-9 16 (17.6/20.6) b1 (24.2/21.7) 0 (neg./22.3)
T16-10 97 (15.3/20.9) b1 (28.0/23.4) 0 (neg./25.0)
T16-11 128 (18.5/24.5) b1 (29.8/26.3) 0 (neg./27.1)
T16-12 181 (18.6/25.1) 11 (24.6/27.1) 0 (neg./27.7)
T16-13 315 (20.4/27.7) 0 (neg./27.6) 16 (24.6/27.6)
SiHa (600 cells) 15 (24.9/28.8)
SiHa (60 cells) 24 (28.3/32.9)
HPV-18
T18-1 30 (18.3/22.2) b1 (29.2/25.8) 0 (neg./25.1)
T18-2 3 (22.0/22.5) 0 (neg./23.0) 0 (neg./25.1)
T18-3 b1 (24.1/22.5) b1 (26.5/25.0) 0 (neg./23.7)
T18-4 X (19.9/pos.) X (30.3/pos.) 0 (neg./pos.)
T18-5 X (19.8/pos.) 0 (neg./neg.) 0 (neg./pos.)
T18-6 X (15.6/n.d.) X (26.3/neg.) 0 (neg./neg.)
T18-7 X (20.9/pos.) X (29.2/neg.) 0 (neg./neg.)
T18-8 2 (24.3/24.4) 0 (neg./24.6) 0 (neg./26.2)
T18-9 111 (19.0/24.8) 0 (neg./27.7) 0 (neg./27.4)
T18-10 6 (23.6/25.2) 0 (neg./24.2) 0 (neg./27.6)
T18-11 2 (21.5/21.5) b1 (24.8/21.1) b1 (26.5/23.3)
T18-12 1 (21.8/20.5) b1 (28.5/22.5) 0 (neg./26.4)
HeLa (600 cells) 30 (25.8/30.6)
HeLa (60 cells) 22 (29.1/34.3)
HPV-16/18
T16/18-1 97 (18.3-HPV-18/23.9) b1 (26.8-HPV-16/22.3) 0 (neg./24.5)
The ﬁrst column lists the clinical/laboratory code of each of 26 cervical carcinomas. The
second, third and fourth column list three numbers, in each case ﬁrst the copy number
of the virus per cell, then the CT value of the HPV-16/18 RT-PCR signal, and thirdly the
CT value of the cellular marker, the HMBS gene. The second column lists data obtained
with tumor samples, the third normal cell clusters ﬂanking the tumors, and the fourth
ﬂanking mesenchymal tissues. Each CT value represents the average of the RT-PCR
values obtained from two DNA preparations made from two juxtaposed LCM samples
cleaved from the same thin section of the tumor. The abbreviations “pos.” and “neg.”
refer to a positive or negative PCR signal, evaluated by gel electrophoresis, in cases
where no quantitative real-time-PCR ampliﬁcation could be achieved. The letter X
replaces the copy number in those cases where the virus, but not the cellular gene as the
denominator of the calculation could be quantiﬁed.
262 M. Kalantari et al. / Virology 390 (2009) 261–267that allow the molecular comparison of cell populations that are
histologically or pathologically distinct although topographically
contiguous. This technique has opened new and successful avenues
for enquiries about molecular histology and pathology in many ﬁelds
of cancer research (for reviews, see Fuller et al., 2003; Espina et al.,
2005; Domazet et al., 2008), but has only been sporadically used in the
analysis of neoplastic tissue from the cervix. In the experiments
reported here, we used LCM to investigate whether HPV DNA can be
sensitively and quantitatively detected in small clusters of archival
(i.e. formalin-ﬁxed and parafﬁn-embedded) samples. We also asked
whether the HPV DNA is restricted to pathologically distinct cells or is
present in adjacent normal cells. This question is of interest in order to
understand the issue of subclinical disease, and to clarify the ill-
deﬁned concept of “latency” in HPV biology and pathogenesis. Lastly,
we added pilot experiments to address whether the same DNA
preparations can be used to study the epigenetics of HPV genomes, a
powerful characteristic of this DNA to identify cancerous progression,
since HPV-16 and HPV-18 genomes are targeted by epigenetic changes
during productive infections and neoplasia of anogenital and oral
lesions (Kalantari et al., 2004; Turan et al., 2006; Balderas-Loaeza et
al., 2007; Kalantari et al., 2008a, 2008b). In these publications we have
reported that single lesion normally contain HPV genomes with
diversemethylation patterns, and that the HPV-16 and 18 L1 genes can
become speciﬁcally hypermethylated in tumors, apparently as a
consequence of recombination between the viral and the cellular DNA.
Results
Overall strategy
This study targeted thin sections of squamous and adenocarcino-
mas of the uterine cervix to address the questions of (i) whether HPV-
16 and HPV-18 DNA can be detected with high sensitivity in groups of
cells ranging from 100 to 2000 cells and in DNA aliquots correspond-
ing to only a small fraction of these cells, (ii) whether we can estimate
the copy number of the viral genomes in the lesion by comparison
with a cellular gene, (iii) whether the viral DNA is present only in
cancerous tissue or also detectable in surrounding histologically
normal epithelial cells and in mesenchyme, and (iv) whether DNA
methylation as an epigenetic characteristics of HPV DNA and
indicative of tumor progression can – in principle – be studied with
these very small samples.
Sensitive detection of HPV-16 and HPV-18 DNA in LCM samples from
archival cervical carcinomas in multiple copies per cell
The ﬁrst column of Table 1 lists the blinded designation of 26
cervical carcinomas sorted by the two HPV types. In the second
column, the values in brackets represent the CT values for HPV DNA
and as internal control the CT value of the cellular single copy gene for
hydroxymethylbilane synthase (HMBS). HPV-16 or HPV-18 DNA could
be detected in all of these samples, although the PCR reaction was
initiated with a DNA amount equivalent to the content of nine to 70
cells only. In addition, we could detect the HMBS gene in 25 of these
26 samples, and quantify it by CT values in 20 samples. The CT values
of different PCR amplicons (and therefore target genes) cannot be
rigorously compared, but they are useful to estimate relative copy
numbers. With this restriction in mind, we have calculated the
number of HPV-16 and 18 genomes per cell of each tumor sample
based on the assumptions that each cell contains two HMBS genes and
that a difference of one unit of the CT values corresponds to a factor of
two. As Table 1 shows, the number of HPV genome copies per cell
varies widely from tumor to tumor, namely between nine and 630
copies for HPV-16 and between one and 111 copies for HPV-18. We
validated the quantiﬁcation of the HPV genomes per cell by including
SiHa and HeLa cells in Table 1. SiHa contains 2 HPV-16 genomes percell and HeLa 50 HPV-18 genomes. Targeting 600 and 60 cells of each
cell line, wemeasured 15 and 23 HPV-16 copies in SiHa cells, a roughly
ninefold overestimate, and 30 and 22 HPV-18 copies in HeLa, a
twofold underestimate. We conclude that the real-time PCR technique
permits a quantitative approach, which is however sensitive to the
identity of the primers and the amplicons. The deviation between the
precision of measuring HPV-16 and 18 is too large to interpret the
quantitative differences we found between HPV-16 and 18 in tumors.
We conclude that a speciﬁc cellular gene aswell as HPVDNA can be
readily detected and with some reliability quantiﬁed in small LCM
generated clusters of formalin-ﬁxed samples. HPV genomes are
normally present at higher copy numbers than cellular genes and
their quantities vary widely from lesion to lesion, and the CT values
allow estimating the ratio between HPV genomes and cellular genes.
HPV-16 and HPV-18 in histologically normal squamous epithelial cells of
the cervix sampled remote from detectable neoplasia
In order to address the questionwhether HPV-16 and HPV-18 DNA
exists outside of the tumor margins, we generated DNA preparations
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the cancerous tissue. The measures that we took to avoid cross-
contamination between the samples have been described above.
In all samples, the heterologous control (kidney) led toHMBS signals
but not to HPV detection (data not shown) excluding contaminations of
the analyzed tissue associated with the manipulation processes.
The third column of Table 1 shows the analysis of normal tissue
outside the histological margins of the tumor. Twenty-two of these 26
samples contained sufﬁcient DNA for diagnoses as judged by HMBS
signals. To our surprise, 16 of these 22 HMBS positive samples also
gave rise to a CT value for HPV-16 or HPV-18. Our precautions and the
much lower detection frequency in stroma samples (see below) make
it very unlikely that these signals originate from cross-contamination.
A contamination by mucus from the tumor is further unlikely, as
tumors do not produce HPV particles, and are unlikely to release pure
HPV DNA, and since many of our cuts of normal tissue avoided the
epithelial surface area, where mucus could spread. We interpret these
signals as evidence for the presence of HPV DNA in histologically
normal cell populations. Notably, however, most samples contained
less than one copy of HPV DNA per cell, indicative of single or smallFig. 1. Distribution of methylated CpG residues at the 3′ ﬂank of L1 and through the LCR of HP
number on the top of the bar the position of this CpG in the genome of HPV-16. Each horizon
end of the L1 gene and the complete long control region. Unmethylated CpGs are indicated b
the borders between amplicons, and discontinuities between supposedly different HPV-1
preferential methylation of the L1 gene has been addressed in detailed by multiple studies fr
2004; Balderas-Loaeza et al., 2007; Kalantari et al., 2008a, 2008b).groups of infected cells among the hundreds analyzed. We interpret
these data as evidence for low copy number replication of HPV DNA in
a subset of histologically normal cells and point to the possibility that
an expanded and reﬁned study using this technology could shed light
on the phenomenon of “latent” infection by HPVs.
The fourth column of Table 1 shows the analysis of stroma
(mesenchyme) samples. Nineteen of the 26 samples gave a CT value
for the HMBS, and another four, where PCR was done without
quantiﬁcation, a positive PCR signal. In other words, 23 samples were
satisfactory for DNA diagnoses. Only four of these 23 samples gave a
RT-PCR signal for HPV, and only one of them indicated a higher copy
number than the HMBS control. This conﬁrms the assumption that
HPVs normally do not infect the stroma. It is not clear if the signals of
four HPV positive samples represent histologically inconspicuous
invasion of the mesenchyme by HPV containing tumor cells, or some
other undeﬁned process.
The last line of Table 1 reports a peculiarity: Tumor T16/18-1
contained HPV-18, while ﬂanking normal tissue generated a signal for
HPV-16, showing that double infection with different HPV types can
occur only a few cell diameters apart from one another.V-16. Each vertical set of rectangles represents one of 19 speciﬁc CpG dinucleotides, the
tal set of rectangles represents a 913 bp segment of the HPV-16 genome, covering the 3′
y white rectangles, methylated by black ones. The two vertical white separators indicate
6 molecules. Further experimental details of this approach and interpretation of the
om our group that targeted cervical, oral, and penile HPV-16 infections (Kalantari et al.,
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These pilot experiments relating to methylation were performed
to explore whether the limited DNA preparations from LCM samples
would permit methylation analyses, considering that the bisulﬁte
technique is much less sensitive than the RT-PCR experiments
reported above. Fig. 1 shows the outcome of studying three of the
previously analyzed tumors, while the analysis of all others
preparations was not possible due to limited sample size. This ﬁgure
reports the methylation status of 19 CpG residues stretching from
the 3′ ﬂank of the HPV-16 L1 gene through the viral long control
region to the promoter for the E6 gene. Details of this documenta-
tion have been reported in our previous publications on biopsies and
cell lines of cervical, oral, and penile HPV-16 associated carcinomas
(Kalantari et al., 2004; Balderas-Loaeza et al., 2007; Kalantari et al.,
2008a, 2008b).
Fig. 1A shows the methylation pattern of HPV-16 in tumor T16-2.
Twenty amplicons represent the methylation state of four contiguous
but separately ampliﬁed short genomic regions of HPV-16, corre-
sponding to the L1 gene, the 5′ part of the LCR, the central LCR, and the
promoter region, of ﬁve independent clones from each region. As
normally observed in tumors, methylation concentrates on the L1
region and is absent from most of the LCR. Fig. 1B represents 40
amplicons from the same genomic region of HPV-16 from tumor T16-
3, and Fig. 1C 40 amplicons from tumor T16-1. Fig. 1D shows 40
amplicons derived from two separate LCM cuts of normal epithelium
ﬂanking tumor T16-1. All samples, representing a total of seven LCM
dissection products, show that the diversity of methylation patterns,
as observed previously in DNA preparations from whole lesions, is
frequent on the microscopic level. There are some identical patterns
among some clones of the same tumor, potential examples of clonal
outgrowth of a cell with a particular epigenetic pattern. L1 gene
hypermethylation, an indicator of integration of HPV into the
chromosomal DNA, is apparent in all twenty L1 amplicons from the
tumor tissue. It is also present in one of the two samples from normal
tissue, while the other sample is unmethylated, indicating epigenetic
changes in normal tissue, possibly due to HPV-cell DNA recombina-
tion, that has not yet become reﬂected in histological changes. Both
cuts from the normal tissue could be considered as histological latent
infection. But while unmethylated HPV genomes are likely episomal
and indicate an infection that may resolve itself, the sample with
methylated HPV genomes likely contains only integrated viral
genomes, a state that is molecularly, although not yet histologically,
committed to progress.
Discussion
This study conﬁrmed that one can detect HPV genomes as well as a
cellular control gene in LCM generated samples from formalin-ﬁxed
and parafﬁn-embedded samples with high sensitivity and in semi-
quantitative manner. We interpreted the CT values generated RT-PCR
experiments. Assuming that each cell contained two alleles of the
HMBS gene, and that a difference in a CT value of one unit identiﬁes
one PCR depending duplication, we detected nine to 630 HPV-16
genome copies and one to 111 HPV-18 genome copies per tumor cell,
respectively. Validation of the CT values against cell lines indicates
that may have to be revised, and that the actual HPV-16 genomes copy
numbers are by a factor of nine lower and the HPV-18 copies by a
factor of two higher than measured. While we attempted to dissect
cancer samples only down to clusters of minimally 100 cells, and
while we did not use DNA dilutions corresponding to the content of
less than nine cells, the measured sensitivities nevertheless suggest
that one can amplify, quantify and characterize the HPV DNA load of
single cells.
Our research also aimed to help to understand the phenomena
of subclinical HPV infections and latency. The term “subclinical HPVinfection” deﬁnes a situation where the DNA tests of smears or
biopsies detect HPV DNA, while cytology and histology cannot
detect abnormal cells nor can lesions be diagnosed by colposcopy.
The term “latency” does not necessarily refer to the same scenario.
While poorly deﬁned in HPV biology, it has a deﬁned meaning in
unrelated viruses. For example, in herpes viruses it refers to deﬁned
stages of the viral life cycle and molecular biology in the absence of
symptoms, and often in other cell types than those that are
involved in disease. While we cannot resolve these matters for
HPVs, our observations suggest that histologically normal squamous
epithelia, contiguous with but remote from cancerous lesions,
harbor HPV genomes. In contrast to tumors, there are often on
the average less than one HPV genome per cell, although we
observed HPV DNA in some normal tissues at nearly equal
concentration as cellular genes, or, in the case of two tumors,
signiﬁcantly exceeding it. We worked with these speciﬁc normal cell
preparations from tumor patients, as we could not sample cervical
tissue biopsies from healthy patients for ethical reasons. Conse-
quently, we do not know whether our observations would only apply
to normal epithelia that are topographically linked to cancerous
tissue, or whether our data describe a subclinical infection in the
absence of any neoplasia. In spite of this limitation, we conclude that
histologically normal squamous epithelia of the cervix can contain
HPV genomes. One can speculate whether this means that these
tissues represent productive infections or merely temporary replica-
tion of fortuitously infected tissue. Future research using our
approach can possibly resolve whether there is a molecular
difference between productive infections in neoplastic precursor
lesions and “latent” infection in normal epithelia. The relevance of
this question has been addressed previously by Abramson et al.
(2004), who observed the presence of HPV-6 and 11 outside the
margins of laryngeal warts, frequently often in the tracheal
epithelium outside the squamous epithelium of the larynx. These
authors proposed that such infections outside of histologically
deﬁned lesions may be the source for postsurgical recurrence of
respiratory papillomatosis (Abramson et al., 2004).
We have previously published on the epigenetic modiﬁcation of
HPV-16 and HPV-18 genomes during carcinogenesis (Kalantari et al.,
2004; Turan et al., 2006, 2007; Balderas-Loaeza et al., 2007; Kalantari
et al., 2008a, 2008b). An important aspect of our data was the
observation that HPV genomes, and speciﬁcally the L1 genes, tend to
become hypermethylated as a consequence of recombination with
cellular DNA. As this occurs frequently during carcinogenesis, but not
during the normal life cycle of HPVs, L1 gene methylation can be
interpreted as a biomarker of cells that have taken an irreversible step
toward the cancerous state. Since methylation studies depend on
bisulﬁte treatment of DNA, which unavoidably involves some covalent
degradation, we have learned in the research reported here that LCM
generated samples are often too small for such epigenetic studies. We
have reported that three cancers, whose DNA preparations were
amenable to methylation studies, showed the expected L1 methyla-
tion. As in the analysis of whole tumors, we observed heterogeneous
methylation patterns, indicating epigenetic diversity even in small
clusters of cells. Surprisingly, two LCM preparations from the normal
tissue close to the same tumor showed L1 methylation and lack of
methylation, respectively. We can only speculate that the methylated
HPV genomes may exist recombined with chromosomal DNA, and the
unmethylated as episomes, suggesting that the former cell population
might have progressed already molecularly in spite of normal
histology. It would also be desirable to compare methylation data
with direct measurements of HPV integration into chromosomes, as
published recently (Kalantari et al., 2008b). Unfortunately, our LCM
research was targeted at formalin-ﬁxed samples, which do not permit
the restriction-ligation approach used in our previous publication, due
to the need of amplicons larger than a few hundred basepairs, which
can only be obtained from fresh samples.
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LCM technique helped to conﬁrm the presence of HPV in
endocervical adenocarcinoma cells (Chew et al., 2005a, 2005b). It
allowed detecting differential expression of cellular genes that
correlated with the tissue substructures of HPV and of cottontail
rabbit papillomavirus lesions (Baumgarth et al., 2004; Kendrick et
al., 2007; Huber et al., 2004). LCM has also been used for DNA
diagnosis of head-and-neck squamous cell carcinomas (HNSCCs)
(Anderson et al., 2007), and to elucidate molecular differences
between HPV containing and HPV independent HNSCCs (Pyeon et
al., 2007). These publications and our data conﬁrm the power of
LCM technology to investigate biological and pathogenic properties
of papillomavirus infections that vary among the diverse cell
populations affected by the virus. Future research may expand our
limited knowledge of the molecular switches during the normal HPV
life cycle and of mutational and epigenetic changes during multistep
carcinogenesis.
Materials and methods
Tissue samples
The tissue samples consisted of formalin-ﬁxed, parafﬁn-
embedded tissues of squamous and glandular cell carcinomas of
the cervix from 26 patients who were biopsied at the Service of
Gynecology at the Instituto Nacional de Cancerologie in Mexico
City, or underwent surgery at the Medical Center of the University
of California Irvine, at the University of Oklahoma Health SciencesFig. 2. Laser capture microdissection of one cluster each of stromal, normal squamous and ca
columnof threemicroscopic pictures shows theﬁxed tissue after thin section, a blue line indicat
after transfer to a test tube. The third column shows the remaining tissue after removal of theCenter, or at the Karolinska University Hospital, Stockholm, Sweden.
Thirteen of these samples contained HPV-16, twelve HPV-18, and
one sample both viruses, based on detection of diagnostic
amplicons after polymerase chain reaction (PCR) with type speciﬁc
oligonucleotide primers. HPV genotypes were conﬁrmed by PCR
analysis of DNA preparations from thin sections that were not LCM
treated following standard DNA extraction procedures and ampli-
ﬁcation with published primers (Kalantari et al., 2004; Turan et al.,
2006).
Laser capture microdissection
From each sample, ﬁve-micrometer sections were applied to
membrane-coated slides with diluted tissue adhesive (TA, Diagnostic
Products Corporation, van Golsteinlaan 26, 7339 GT Apeldoorn, the
Netherlands) and stained with hematoxylin and eosin (HE). The
margins of cancerous cell populations were microscopically deﬁned
and labeled by one of the pathologists in our team (R.Z., D.P.M). A
Leica AS LMC Laser Microbeam Microdissection microscope with a
0.5 μm laser beam was used to dissect groups of variable numbers of
cells, normally approximately 1000, but varying for some samples
from 100 to 2000 cells. These dissected cell clusters were captured in
test tubes after release from the inverted slide. Fig. 2 exempliﬁes the
LCM generated separation of stromal, normal squamous epithelial and
cancerous tissue from the same tumor biopsy.
The possibility that contaminations may occur in the microtome
was eliminated by using disposable blades. In order to minimize
and monitor DNA contaminations by vapor potentially set freencerous cells from a thin section of a biopsy of a cervical squamous carcinoma. The ﬁrst
ing theprogrammedpathof the laser beam. The second column shows the cleaved sample
experimental sample. The three cuts were targeted at the same thin section of a tumor.
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(supposed to have no HPV DNA), followed by histologically normal
epithelial tissue (possibly not having HPV DNA), and only as the
last step the carcinoma tissue, whose analysis gave rise to the
tumor CT values in the ﬁrst column of Table 1 as discussed above.
In order to avoid contamination of the mesenchymal or normal
epithelial cell preparations by imprecise dissection, we kept a space
of at least ﬁve to ten cell diameter, i.e. about 50 μm, between the
histologically deﬁned margin of the tumor and the non-cancerous
tissues.
DNA preparation
LCM generated samples were mixed with 140 μl digestion buffer
(50 mM Tris–HCl, 1 mM EDTA, 0.5% Tween-20) and 100 μg Proteinase
K and incubated overnight at 37°C followed by 10 min incubation at
90°C. Five out of 140 μl of each DNA preparationwas taken directly for
all PCR analyses without further puriﬁcation. This volume corre-
sponded to the DNA of about nine to 70 cells depending on the size of
the LCM cleaved cell cluster. DNA methylation analyses were
attempted by bisulﬁte treatment of the DNA preparations followed
by PCR, cloning of the ampliﬁcation product into E. coli vectors, and
DNA sequencing.
Detection and quantiﬁcation of HPV-16 and 18 DNA
We used a real-time PCR approach to detect and quantify HPV-16
and 18 DNA. The principles of the probe technology, frequently
referred to as TaqMan probes, have been published (Morris et al.,
1996; Clement and Benhattar, 2005). For detection of HPV-16, we used
oligos targeting the L1 gene of the virus as published by Moberg et al.,
2003, namely F16E7 (5′-AGCTCAGAGGAGGAGGATGAA-3′) and R16E7
(5′-GGTTACAATATTGTAATGGGCTC-3′) for ampliﬁcation and as Taq-
Man probe Pb1.1 (FAM-CCAGCTGGACAAGCAGAACCGG-TAMRA)
linked to the 5′ ﬂuorescent reporter dye (6FAM) and a 3′ quencher
(TAMRA). For detection of HPV-18, we used F18E1 (5′-CATTTTGT-
GAACAGGCAGAGC-3′) and R18E1 (5′-ACTTGTGCATCATTGTGGACC-3′)
for ampliﬁcation and as a TaqMan probe Pb1.2 (VIC-AGAGACAGCA-
CAGGCATTGTTCCATG-TAMRA). The human single copy gene for
hydroxymethylbilane synthase (HMBS, GenBank accession no.
M95623.1) served as positive ampliﬁcation control with the primers
and probes described by Moberg et al., 2003: HMBS-F (5′-
GCCTGCAGTTTGAAATCAGTG-3′), HMBS-R (5′-CGGGACGGGCTT-
TAGCTA-3′) and the TaqMan probe VIC-TGGAAGCTAATGGGAAGCC-
CAGTACC-TAMRA.
Each analysis began with a preampliﬁcation, followed by
quantitative RT-PCR ampliﬁcation, using the same primers for
both reactions. In the initial reaction, 4 μl of crude lysate was pre-
ampliﬁed using 6.25 μl TaqMan preamp Master Mix kit (ABI), 1.6 μl
of a mix of primers for HPV-16, HPV-18 and HMBS, and 1.15 μl
water (total volume 13 μl) after an initial extension for 10 min at
95 °C in 14 cycles (15 s, 95 °C, 4 min, 60 °C). The reaction product
was diluted 1:10, and 4 μl were ampliﬁed and quantiﬁed with an
ABIprism 7900HT instrument, in reaction volume of 25 μl contain-
ing 1×Taqman Universal PCR Mastermix (Applied Biosystems),
0.6 μM of each primer and 0.2 μM of Taqman probe. The thermal
cycler conditions were 10 min denaturation at 94 °C, and 45 cycles
of 15 s at 94 °C and 1 min at 58 °C. The results were analyzed
using ABIPrism's SDS v2.1 software.
Bisulﬁte sequencing
All procedures for determining the methylation status of the HPV-
16 and 18 L1 genes and long control regions (LCRs) after bisulﬁte
modiﬁcation (Frommer et al., 1992), the design of primers for
ampliﬁcation of bisulﬁte treated DNA, and the sequencing of theampliﬁcation products after cloning into E. coli vectors have been
described in detail (Kalantari et al., 2004; Turan et al., 2006; Kalantari
et al., 2008a, 2008b).
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